Totect Approval History
FDA Approved: Yes (First approved September 6, 2007)
Brand name: Totect
Generic name: dexrazoxane
Company: TopoTarget A/S
Treatment for: Anthracycline Extravasation
Totect (dexrazoxane) is a topoisomerase inhibitor used as a detoxifying agent for the treatment of extravasation resulting from intravenous anthracycline chemotherapy.
Development History and FDA Approval Process for Totect
|Sep 7, 2007||Totect Approved in the United States|
|May 31, 2007||TopoTarget elaborates on the specific initiatives to obtain FDA approval of Totect|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.